Management of osteoporosis

[1]  Jung-Tung Liu,et al.  Balloon kyphoplasty versus vertebroplasty for treatment of osteoporotic vertebral compression fracture: a prospective, comparative, and randomized clinical study , 2010, Osteoporosis International.

[2]  J. Eisman,et al.  Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  David J. Wilson,et al.  A randomized trial of vertebroplasty for osteoporotic spinal fractures. , 2009, The New England journal of medicine.

[4]  R. Buchbinder,et al.  A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. , 2009, The New England journal of medicine.

[5]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[6]  B. Steele,et al.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study , 2009, Osteoporosis International.

[7]  S. Boonen,et al.  Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  S. Khosla,et al.  New selective estrogen and androgen receptor modulators , 2009, Current opinion in rheumatology.

[9]  J. Ringe,et al.  Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis , 2009, Rheumatology International.

[10]  H. Taylor.  Designing the ideal selective estrogen receptor modulator-an achievable goal? , 2009, Menopause.

[11]  L. Assael,et al.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[12]  S. Silverman.  Selecting Patients for Osteoporosis Therapy , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  D. Kiel,et al.  Dietary Calcium and Serum 25‐Hydroxyvitamin D Status in Relation to BMD Among U.S. Adults , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  Kim Brixen,et al.  Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS) , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  S. Judd,et al.  Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. , 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  E John Orav,et al.  Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.

[17]  H. Genant,et al.  Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment , 2009, Current medical research and opinion.

[18]  R. Recker,et al.  Safety of bisphosphonates in the treatment of osteoporosis. , 2009, The American journal of medicine.

[19]  S. Silverman,et al.  Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. , 2009, The American journal of medicine.

[20]  I. Reid,et al.  The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. , 2009, The Journal of clinical endocrinology and metabolism.

[21]  V. Vogel.  The NSABP Study of Tamoxifen and Raloxifene (STAR) trial , 2009, Expert review of anticancer therapy.

[22]  R. O’Keefe,et al.  Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  A. Bergland,et al.  Risk of hip fractures in soft protected, hard protected, and unprotected falls , 2008, Injury Prevention.

[25]  S. Boonen,et al.  Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. , 2008, The Journal of clinical endocrinology and metabolism.

[26]  S. Boonen,et al.  Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  M. Tinetti.  Multifactorial Fall‐Prevention Strategies: Time to Retreat or Advance , 2008, Journal of the American Geriatrics Society.

[28]  A. Campbell,et al.  Effectiveness of a Falls‐and‐Fracture Nurse Coordinator to Reduce Falls: A Randomized, Controlled Trial of At‐Risk Older Adults , 2008, Journal of the American Geriatrics Society.

[29]  W. J. Mulder,et al.  Lack of Effectiveness of a Multidisciplinary Fall‐Prevention Program in Elderly People at Risk: A Randomized, Controlled Trial , 2008, Journal of the American Geriatrics Society.

[30]  B. Carlin,et al.  Effect of dissemination of evidence in reducing injuries from falls. , 2008, The New England journal of medicine.

[31]  Jacques P. Brown,et al.  Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. , 2008, The Journal of rheumatology.

[32]  T. Spector,et al.  Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. , 2008, Arthritis and rheumatism.

[33]  D. Lorich,et al.  Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.

[34]  Kenneth A. Harris,et al.  Association between alcohol consumption and both osteoporotic fracture and bone density. , 2008, The American journal of medicine.

[35]  R. Lindsay,et al.  Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy , 2008, Osteoporosis International.

[36]  F. McAlister,et al.  Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial , 2008, Canadian Medical Association Journal.

[37]  L. Melton,et al.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA , 2008, Osteoporosis International.

[38]  C. Christiansen,et al.  Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  P. Miller,et al.  Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  S. Boonen,et al.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2007, The New England journal of medicine.

[41]  M Alan Brookhart,et al.  Osteoporosis Improvement: A Large‐Scale Randomized Controlled Trial of Patient and Primary Care Physician Education , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[43]  K. Kavanagh,et al.  Bisphosphonates , 2007, Annals of the New York Academy of Sciences.

[44]  J. Wark,et al.  The effects of smoking on bone health. , 2007, Clinical science.

[45]  J. Bilezikian,et al.  Bone turnover 18 months after a single intravenous dose of zoledronic acid , 2007, International journal of clinical practice.

[46]  R. Baron,et al.  Wnt signaling and the regulation of bone mass , 2007, Current osteoporosis reports.

[47]  G. Karsenty,et al.  In vivo analysis of Wnt signaling in bone. , 2007, Endocrinology.

[48]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[49]  E. Lewiecki,et al.  A review of strontium ranelate and its effect on DXA scans. , 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[50]  J. Eisman,et al.  Risk factors for fracture in nonosteoporotic men and women. , 2007, The Journal of clinical endocrinology and metabolism.

[51]  E. Briganti,et al.  Exercise and Calcium Combined Results in a Greater Osteogenic Effect Than Either Factor Alone: A Blinded Randomized Placebo‐Controlled Trial in Boys , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  O. Vasiljeva,et al.  Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.

[53]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[54]  M. Tinetti,et al.  Fall-risk evaluation and management: challenges in adopting geriatric care practices. , 2006, The Gerontologist.

[55]  R. Marcus,et al.  Osteosarcoma and Teriparatide? , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  T. Keaveny,et al.  Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  M. Drezner,et al.  Osteonecrosis of the Jaw: More Research Needed , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[58]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[59]  S. Boonen,et al.  Strontium Ranelate Reduces the Risk of Vertebral and Nonvertebral Fractures in Women Eighty Years of Age and Older , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[60]  C. Christiansen,et al.  Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. , 2006, Arthritis and rheumatism.

[61]  Y. Yazici,et al.  Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.

[62]  J. Kalmar,et al.  Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws , 2006, Annals of Internal Medicine.

[63]  O. MacDougald,et al.  Regulation of bone mass by Wnt signaling. , 2006, The Journal of clinical investigation.

[64]  C. Turner,et al.  Bone Strength: Current Concepts , 2006, Annals of the New York Academy of Sciences.

[65]  T. Spector,et al.  Strontium Ranelate Reduces the Risk of Vertebral Fractures in Patients With Osteopenia , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  K. Ishikawa-Takata,et al.  The effects of Tai Chi Chuan on physiological function and fear of falling in the less robust elderly: an intervention study for preventing falls. , 2006, Archives of gerontology and geriatrics.

[67]  P. Farahmand,et al.  Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study , 2006, Rheumatology International.

[68]  C. Deal,et al.  Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety , 2006, Women's health.

[69]  M. Drezner,et al.  Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study , 2005, Annals of the rheumatic diseases.

[70]  S. Boonen,et al.  Safety and Efficacy of Risedronate in Patients With Age‐Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[71]  A. Tashjian,et al.  Teriparatide [Human PTH(1‐34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[72]  E. Schwartz,et al.  Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[73]  S. Cummings,et al.  Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[74]  D. Newitt,et al.  Effects of Salmon Calcitonin on Trabecular Microarchitecture as Determined by Magnetic Resonance Imaging: Results From the QUEST Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[76]  R. Lindsay,et al.  Daily and cyclic parathyroid hormone in women receiving alendronate. , 2005, The New England journal of medicine.

[77]  G. Dalsky,et al.  Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.

[78]  G. Chatellier,et al.  Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism , 2005, BMJ : British Medical Journal.

[79]  Kenton R Kaufman,et al.  Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. , 2005, Mayo Clinic proceedings.

[80]  Steven L Wolf,et al.  Reduction in Fear of Falling Through Intense Tai Chi Exercise Training in Older, Transitionally Frail Adults , 2005, Journal of the American Geriatrics Society.

[81]  G. Dalsky,et al.  Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[82]  Anna Nordström,et al.  Bone gained from physical activity and lost through detraining: a longitudinal study in young males , 2005, Osteoporosis International.

[83]  W. Grant,et al.  Benefits and requirements of vitamin D for optimal health: a review. , 2005, Alternative medicine review : a journal of clinical therapeutic.

[84]  C. Cooper,et al.  Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial , 2005, The Lancet.

[85]  J. Reginster,et al.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.

[86]  J. Kaufman,et al.  Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy , 2005, Osteoporosis International.

[87]  H. Genant,et al.  Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. , 2005, The Journal of clinical endocrinology and metabolism.

[88]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[89]  M. D. de Broe,et al.  Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats. , 2005, Kidney international.

[90]  A. LaCroix,et al.  Risk Factors Associated with Acute Pyelonephritis in Healthy Women , 2005, Annals of Internal Medicine.

[91]  H. Meinzer,et al.  Treatment of Painful Vertebral Fractures by Kyphoplasty in Patients With Primary Osteoporosis: A Prospective Nonrandomized Controlled Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[92]  K. Prestwood,et al.  Bone health and aging: implications for menopause. , 2004, Endocrinology and metabolism clinics of North America.

[93]  S. Cummings,et al.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.

[94]  Hiroshi Ohshima,et al.  Intravenous Pamidronate Prevents Femoral Bone Loss and Renal Stone Formation During 90‐Day Bed Rest , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[95]  C. Christiansen,et al.  Changes in bone density and turnover after alendronate or estrogen withdrawal , 2004, Menopause.

[96]  D. Mellström,et al.  Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.

[97]  S. Dhaliwal,et al.  Physical Activity and Calcium Consumption Are Important Determinants of Lower Limb Bone Mass in Older Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[98]  I. Lieberman,et al.  Primary and Secondary Osteoporosis' Incidence of Subsequent Vertebral Compression Fractures After Kyphoplasty , 2004, Spine.

[99]  S. Cummings,et al.  Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.

[100]  Richard Eastell,et al.  Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. , 2004, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[101]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[102]  E. Barrett-Connor,et al.  Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[103]  W. Flanders,et al.  The association between physical activity and forearm bone mineral density in healthy premenopausal women. , 2004, Journal of women's health.

[104]  B. Ettinger,et al.  Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[105]  J. Manson,et al.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial , 2004 .

[106]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[107]  R. Chlebowski,et al.  Estrogen plus progestin and colorectal cancer in postmenopausal women. , 2004, The New England journal of medicine.

[108]  H. Minne,et al.  Effects of a New Spinal Orthosis on Posture, Trunk Strength, and Quality of Life in Women with Postmenopausal Osteoporosis: A Randomized Trial , 2004, American journal of physical medicine & rehabilitation.

[109]  R. Eastell,et al.  The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[110]  Johanna W Lampe,et al.  Antibiotic use in relation to the risk of breast cancer , 2004, JAMA.

[111]  C. Rubin,et al.  Prevention of Postmenopausal Bone Loss by a Low‐Magnitude, High‐Frequency Mechanical Stimuli: A Clinical Trial Assessing Compliance, Efficacy, and Safety , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[112]  L. Hofbauer,et al.  Novel Aspects on RANK Ligand and Osteoprotegerin in Osteoporosis and Vascular Disease , 2003, Calcified Tissue International.

[113]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[114]  J. Finkelstein,et al.  The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.

[115]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[116]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[117]  E. Barrett-Connor,et al.  Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study , 2003, Menopause.

[118]  O. Johnell,et al.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. , 2003, Bone.

[119]  M. Kulldorff,et al.  Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. , 2003, JAMA.

[120]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[121]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[122]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[123]  M. Grabois,et al.  Health Professional's Guide to Rehabilitation of the Patient with Osteoporosis , 2003, Osteoporosis International.

[124]  Lex M Bouter,et al.  Prevention of hip fractures by external hip protectors: a randomized controlled trial. , 2003, JAMA.

[125]  Cecilia A. Hale,et al.  Calcium Absorption Varies within the Reference Range for Serum 25-Hydroxyvitamin D , 2003, Journal of the American College of Nutrition.

[126]  A. Licata.  Osteoporosis in men: suspect secondary disease first. , 2003, Cleveland Clinic journal of medicine.

[127]  U. Barzel.  Recommended testing in patients with low bone density. , 2003, The Journal of clinical endocrinology and metabolism.

[128]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.

[129]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[130]  M. Holick,et al.  Vitamin D and bone health in postmenopausal women. , 2003, Journal of women's health.

[131]  R. Lew,et al.  Effects of Vitamin D and Calcium Supplementation on Falls: A Randomized Controlled Trial , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[132]  C. Cooper,et al.  Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. , 2003, Bone.

[133]  P. Gerdhem,et al.  Effects of Cigarette-Smoking on Bone Mass as Assessed by Dual-Energy X-ray Absorptiometry and Ultrasound , 2002, Osteoporosis International.

[134]  H. Deutschmann,et al.  Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density , 2002, Journal of internal medicine.

[135]  M. Kulldorff,et al.  Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[136]  J. Gallagher,et al.  Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. , 2002, The Journal of clinical endocrinology and metabolism.

[137]  Gynecologists.  ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002. , 2002, Obstetrics and gynecology.

[138]  D. Bauer,et al.  Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? , 2002, Mayo Clinic proceedings.

[139]  D. Meier,et al.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. , 2002, The Journal of clinical endocrinology and metabolism.

[140]  R. Heaney.  Effects of caffeine on bone and the calcium economy. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[141]  S. Cummings,et al.  Does Follow-up of Osteoporotic Women Treated with Antiresorptive Therapies Improve Effectiveness? , 2002, Osteoporosis International.

[142]  Jacques P. Brown,et al.  The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis , 2002, Calcified Tissue International.

[143]  G. Guyatt,et al.  V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women , 2002 .

[144]  C. Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[145]  M. Schlichting,et al.  Combined Calcium and Vitamin D3 Supplementation in Elderly Women: Confirmation of Reversal of Secondary Hyperparathyroidism and Hip Fracture Risk: The Decalyos II Study , 2002, Osteoporosis International.

[146]  B. Chabner,et al.  Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1‐34 in the Treatment of Osteoporosis in Men and Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[147]  W. O'Fallon,et al.  Secondary osteoporosis and the risk of distal forearm fractures in men and women. , 2002, Bone.

[148]  P. Delmas,et al.  Treatment of postmenopausal osteoporosis , 2002, The Lancet.

[149]  Hashem Younes,et al.  Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. , 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[150]  J. Adachi,et al.  Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.

[151]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[152]  E. Barrett-Connor,et al.  Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial , 2002 .

[153]  G. Mundy.  Osteoporosis: pathophysiology and non-pharmacological management. , 2001, Best practice & research. Clinical rheumatology.

[154]  R Mendelsohn,et al.  Spectroscopic Characterization of Collagen Cross‐Links in Bone , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[155]  P. Kostenuik,et al.  OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. , 2001, Endocrinology.

[156]  S. Adami,et al.  Alendronate for the Treatment of Osteoporosis in Men , 2001, Calcified Tissue International.

[157]  C. Rey,et al.  Mechanisms of Action and Therapeutic Potential of Strontium in Bone , 2001, Calcified Tissue International.

[158]  P. Fratzl,et al.  Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. , 2001, Bone.

[159]  Mark A. Reiley,et al.  New Technologies in Spine: Kyphoplasty and Vertebroplasty for the Treatment of Painful Osteoporotic Compression Fractures , 2001, Spine.

[160]  J. Manson,et al.  Clinical practice. Postmenopausal hormone-replacement therapy. , 2001, The New England journal of medicine.

[161]  D. Torgerson,et al.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.

[162]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[163]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[164]  J. Gallagher,et al.  Role of estrogens in the management of postmenopausal bone loss. , 2001, Rheumatic diseases clinics of North America.

[165]  C. Christiansen,et al.  Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. , 2000, Archives of internal medicine.

[166]  P Kannus,et al.  Prevention of hip fracture in elderly people with use of a hip protector. , 2000, The New England journal of medicine.

[167]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[168]  J. Rodriguez-Portales,et al.  Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[169]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[170]  P. Kostenuik,et al.  Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis , 2000, The Journal of experimental medicine.

[171]  C. Rosen,et al.  Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. , 2000, The Journal of clinical endocrinology and metabolism.

[172]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[173]  J. Reginster,et al.  Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[174]  M. Davie,et al.  Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men , 2000, Annals of the rheumatic diseases.

[175]  J A Stevens,et al.  Reducing falls and resulting hip fractures among older women. , 2000, Home care provider.

[176]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .

[177]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.

[178]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[179]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[180]  V. Beral,et al.  Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.

[181]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[182]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[183]  F. Grodstein,et al.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.

[184]  M. D. de Broe,et al.  Strontium and Bone , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[185]  J. Glowacki,et al.  Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. , 1999, JAMA.

[186]  G. Colditz,et al.  Smoking, smoking cessation, and risk of hip fracture in women. , 1999, The American journal of medicine.

[187]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[188]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[189]  B. Riggs,et al.  Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[190]  E. Barrett-Connor.  Fortnightly review: Hormone replacement therapy , 1998 .

[191]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[192]  M. Holick,et al.  Redefining vitamin D insufficiency , 1998, The Lancet.

[193]  J. Eisman,et al.  Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial , 1998, Annals of Internal Medicine.

[194]  J. Digennaro,et al.  Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. , 1998, The Journal of clinical endocrinology and metabolism.

[195]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[196]  G. Lyritis,et al.  Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. , 1997, Acta orthopaedica Scandinavica. Supplementum.

[197]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[198]  Jacques P. Brown,et al.  Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.

[199]  R. Balena,et al.  The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. , 1997, The American journal of medicine.

[200]  J. Levine,et al.  Esophageal stricture associated with alendronate therapy. , 1997, The American journal of medicine.

[201]  Ego Seeman,et al.  Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.

[202]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[203]  Kenneth K Wang,et al.  Esophagitis associated with the use of alendronate. , 1996, The New England journal of medicine.

[204]  I. Reid,et al.  The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.

[205]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[206]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[207]  M. Tinetti,et al.  A multifactorial intervention to reduce the risk of falling among elderly people living in the community. , 1994, The New England journal of medicine.

[208]  L. Rubenstein,et al.  Falls in the Nursing Home , 1994, Annals of Internal Medicine.

[209]  K. Overgaard.  Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study , 1994, Calcified Tissue International.

[210]  I. Reid,et al.  Effect of calcium supplementation on bone loss in postmenopausal women. , 1993, The New England journal of medicine.

[211]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[212]  C. Slemenda,et al.  Calcium supplementation and increases in bone mineral density in children. , 1992, The New England journal of medicine.

[213]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[214]  R. Prince,et al.  Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. , 1991, The New England journal of medicine.

[215]  B. Dawson-Hughes,et al.  A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. , 1990 .

[216]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[217]  H. Genant,et al.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[218]  M. Tinetti,et al.  Prevention of falls among the elderly. , 1989, The New England journal of medicine.

[219]  Chang Lw,et al.  Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. , 1989 .

[220]  C. Christiansen,et al.  Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. , 1987, The New England journal of medicine.

[221]  H. DeLuca,et al.  Strontium Induced Rickets: Metabolic Basis , 1971, Science.

[222]  G. Keating,et al.  Raloxifene , 2012, Drugs.

[223]  P. Sambrook.  Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw , 2009, Nature Clinical Practice Rheumatology.

[224]  E. Seeman.  Loading and bone fragility , 2009, Journal of Bone and Mineral Metabolism.

[225]  P. Kostenuik,et al.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.

[226]  N. Hamdy.  Denosumab: RANKL inhibition in the management of bone loss. , 2008, Drugs of today.

[227]  G. Dalsky,et al.  Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results , 2008 .

[228]  E. Brown,et al.  The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. , 2007, Sub-cellular biochemistry.

[229]  M. Passeri,et al.  Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study , 2007, Calcified Tissue International.

[230]  David J Torgerson,et al.  Primary care Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D 3 ) for prevention of fractures in primary care , 2005 .

[231]  E. Barrett-Connor,et al.  The rise and fall of menopausal hormone therapy. , 2005, Annual review of public health.

[232]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[233]  W. Nagler,et al.  Current medical, rehabilitation, and surgical management of vertebral compression fractures. , 2003, Journal of women's health.

[234]  O. Johnell,et al.  Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. , 2002, Bone.

[235]  Kay Dickersin,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2000, NIH consensus statement.

[236]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[237]  S. Epstein,et al.  Drug-Induced Bone Loss , 2000, Osteoporosis International.

[238]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[239]  P. Beighton,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(12):6392–6395 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2005-1235 Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers , 2022 .